FDA Poised to Approve Pfizer COVID-19 Vaccine as U.S. Death Toll Mounts
By [Your Name], [News Outlet]
Date
The U.S. Food and Drug Administration is set to grant emergency use authorization for Pfizer’s COVID-19 vaccine, according to U.S. Department of Health and Human Services Secretary Alex Azar. The green light could come within days, marking a critical step in the nation’s fight against the deadly pandemic.
“The FDA informed Pfizer that they do intend to proceed toward an authorization for their vaccine,” Azar told ABC News on Friday. He added that approval is expected “in the next couple of days,” paving the way for initial immunizations to begin as early as Monday or Tuesday.
In a statement, the FDA confirmed it is working swiftly to finalize the emergency use authorization (EUA) and has notified both the Centers for Disease Control and Prevention and Operation Warp Speed to prepare for immediate distribution.
The move follows a resounding endorsement from an independent advisory panel on Thursday, which voted overwhelmingly in favor of authorizing the vaccine for public use. The endorsement comes as the United States continues to see devastating losses from COVID-19, with 2,902 deaths reported on Thursday, just one day after a record 3,253 fatalities.
Pfizer, in partnership with German firm BioNTech, has requested approval for its two-dose vaccine in individuals aged 16 to 85. The vaccine demonstrated 95 percent efficacy in late-stage trials and has already been approved for use in the United Kingdom, where immunizations began earlier this week. Canada and Bahrain have also cleared the vaccine, with Canadian officials planning to begin vaccinations next week.
Despite the scientific progress, the vaccine rollout is not without political controversy. Outgoing President Donald Trump has repeatedly criticized the FDA for delays in authorizing the vaccine, accusing both the agency and Pfizer of unnecessarily slow progress. Following the FDA’s statement, Trump again voiced frustration, targeting FDA Commissioner Stephen Hahn for the agency’s timeline.
Public Skepticism Lingers
While the authorization marks a significant milestone, public hesitation remains a hurdle. A new Reuters/Ipsos poll conducted from December 2-8 shows that just 61 percent of Americans are currently open to getting vaccinated, down four percentage points from a similar survey in May.
The poll highlights a significant gender gap: only 55 percent of women expressed interest in receiving the vaccine, down six points from May, while male interest remained steady at 68 percent. Women also reported a rise in vaccine skepticism, with 35 percent saying they were “not very” or “not at all” likely to get vaccinated—up nine points since May.
Political affiliation also appears to influence attitudes. While 75 percent of Democrats expressed willingness to be vaccinated, only 53 percent of Republicans said the same. Racial disparities persist as well, with just 49 percent of African Americans showing interest in the vaccine, compared to 63 percent of white respondents and 61 percent of Hispanics.
Age is another dividing factor: younger adults (ages 18-34) were less inclined to get vaccinated (56 percent) compared to 69 percent of those aged 55 and older.
The national survey polled 4,419 adults online in English, including 1,216 who said they were not interested in getting the vaccine. The poll carries a credibility interval of roughly two percentage points overall and five points for smaller demographic groups.
As the FDA moves closer to authorizing the vaccine, health officials face the dual challenge of logistics and public trust. The coming days will test both.
